D3 Creatine
Changes in muscle mass using the D3-creatine dilution method and function in DMD
The D3Cr dilution method, along with a comprehensive evaluation of muscle function and strength, will be used to assess 1-year changes in functional capacity and muscle mass. In this way, variability in the rate of change will be assessed. The D3Cr dilution method is non-invasive and is well-suited for a multi-center trial.
They will be recruiting DMD participants between the ages of 5 – 25 years to represent a broad spectrum of disease state, and will recruit 150 patients across 3 sites: Duke University Medical Center, US, The University of Utah, US, Newcastle University, UK, and Newcastle upon Tyne NHS Foundation Trust, UK, in collaboration with the University of California, Berkeley, US.
Primary Outcome Measures
To measure longitudinal changes in functional capacity and functional skeletal muscle mass using the D3Cr dilution method in participants with DMD.
Can I take part?
Inclusion Criteria
- Confirmed diagnosis of DMD based on genetic testing and clinical history consistent with the diagnosis.
- Gender: Male
- For ambulatory patients: ability to walk 10 metres
Exclusion Criteria
- Phenotypic and/or genetic and/or histological evidence of dystrophinopathy compatible with Becker Muscular Dystrophy
- Continued use of creatine supplements (no use of creatine supplements for at least 2 months prior to enrolment).
Age
5 - 25 years
Mutation Specific
Muscle Biopsy
Not Required
Ambulation
both